Versant’s global biotech team is reloading with $350M-plus fund
After racking up dozens of biotech investments on both sides of the Atlantic over the past 17 years, the prolific and influential team at Versant Ventures is aiming at stepping up with a new, $350 million-plus fund that will push past the $2 billion mark on the money it manages.
Brad Bolzon, Jerel Davis and the rest of the managing partners have signed up to assemble the next fund, Versant Venture Capital VI, according to a filing with the SEC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
